-
Something wrong with this record ?
Excellent Glycemic Control Maintained by Open-Source Hybrid Closed-Loop AndroidAPS During and After Sustained Physical Activity
L. Petruzelkova, J. Soupal, V. Plasova, P. Jiranova, V. Neuman, L. Plachy, S. Pruhova, Z. Sumnik, B. Obermannova,
Language English Country United States
Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
30285476
DOI
10.1089/dia.2018.0214
Knihovny.cz E-resources
- MeSH
- Exercise physiology MeSH
- Diabetes Mellitus, Type 1 blood drug therapy physiopathology MeSH
- Child MeSH
- Glycated Hemoglobin metabolism MeSH
- Hypoglycemia etiology prevention & control MeSH
- Hypoglycemic Agents administration & dosage MeSH
- Insulin administration & dosage MeSH
- Insulin Infusion Systems * MeSH
- Blood Glucose metabolism MeSH
- Humans MeSH
- Skiing physiology MeSH
- Adolescent MeSH
- Pilot Projects MeSH
- Blood Glucose Self-Monitoring instrumentation methods MeSH
- Feasibility Studies MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVE: Officially licensed hybrid closed-loop systems are not currently available worldwide; therefore, open-source systems have become increasingly popular. Our aim was to assess the safety, feasibility, and efficacy of an open-source hybrid closed-loop system (AndroidAPS) versus SmartGuard® technology for day-and-night glucose control in children under extreme sports conditions. RESEARCH DESIGN AND METHODS: Twenty-two children (16 girls, 6-15 years of age, median HbA1c 56 ± 9 mmol/mol) were enrolled in this pivotal winter sports camp study. The participants were divided into two groups using either the AndroidAPS or SmartGuard technology. Physical exertion was represented by all-day alpine skiing. The primary endpoints were mean glucose level, time below the threshold of 3.9 mmol/L, and time within the target range of 3.9 to 10 mmol/L. RESULTS: The children using the AndroidAPS had significantly lower mean glycemia levels (7.2 ± 2.7 vs. 7.7 ± 2.8 mmol/L; 129.6 ± 49 vs. 138.6 ± 50 mg/dL, P < 0.042) than the children using the SmartGuard. The proportion of time below the target (median 5.0% ± 2.5% vs. 3.0% ± 2.3%, P = 0.6) and in the target zone (63% ± 9.5% vs. 63% ± 18%, P = 0.5) did not significantly differ. The AndroidAPS group experienced more frequent malfunctions of the cannula set (median 0.8 ± 0.4 vs. 0.2 ± 0.4, P = 0.02), which could have affected the results. No significant difference was found in the amount of carbohydrates consumed for the prevention and treatment of hypoglycemia [median 40 ± 23 vs. 25 ± 29 g/(patient ·3 days)]. No episodes of severe hypoglycemia or other serious adverse events were noted. CONCLUSIONS: This pilot study showed that the AndroidAPS system was a safe and feasible alternative to the SmartGuard Technology.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012305
- 003
- CZ-PrNML
- 005
- 20190905105830.0
- 007
- ta
- 008
- 190405s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1089/dia.2018.0214 $2 doi
- 035 __
- $a (PubMed)30285476
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Petruzelkova, Lenka $u 1 Department of Pediatrics, University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 245 10
- $a Excellent Glycemic Control Maintained by Open-Source Hybrid Closed-Loop AndroidAPS During and After Sustained Physical Activity / $c L. Petruzelkova, J. Soupal, V. Plasova, P. Jiranova, V. Neuman, L. Plachy, S. Pruhova, Z. Sumnik, B. Obermannova,
- 520 9_
- $a OBJECTIVE: Officially licensed hybrid closed-loop systems are not currently available worldwide; therefore, open-source systems have become increasingly popular. Our aim was to assess the safety, feasibility, and efficacy of an open-source hybrid closed-loop system (AndroidAPS) versus SmartGuard® technology for day-and-night glucose control in children under extreme sports conditions. RESEARCH DESIGN AND METHODS: Twenty-two children (16 girls, 6-15 years of age, median HbA1c 56 ± 9 mmol/mol) were enrolled in this pivotal winter sports camp study. The participants were divided into two groups using either the AndroidAPS or SmartGuard technology. Physical exertion was represented by all-day alpine skiing. The primary endpoints were mean glucose level, time below the threshold of 3.9 mmol/L, and time within the target range of 3.9 to 10 mmol/L. RESULTS: The children using the AndroidAPS had significantly lower mean glycemia levels (7.2 ± 2.7 vs. 7.7 ± 2.8 mmol/L; 129.6 ± 49 vs. 138.6 ± 50 mg/dL, P < 0.042) than the children using the SmartGuard. The proportion of time below the target (median 5.0% ± 2.5% vs. 3.0% ± 2.3%, P = 0.6) and in the target zone (63% ± 9.5% vs. 63% ± 18%, P = 0.5) did not significantly differ. The AndroidAPS group experienced more frequent malfunctions of the cannula set (median 0.8 ± 0.4 vs. 0.2 ± 0.4, P = 0.02), which could have affected the results. No significant difference was found in the amount of carbohydrates consumed for the prevention and treatment of hypoglycemia [median 40 ± 23 vs. 25 ± 29 g/(patient ·3 days)]. No episodes of severe hypoglycemia or other serious adverse events were noted. CONCLUSIONS: This pilot study showed that the AndroidAPS system was a safe and feasible alternative to the SmartGuard Technology.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a krevní glukóza $x metabolismus $7 D001786
- 650 _2
- $a selfmonitoring glykemie $x přístrojové vybavení $x metody $7 D015190
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a diabetes mellitus 1. typu $x krev $x farmakoterapie $x patofyziologie $7 D003922
- 650 _2
- $a cvičení $x fyziologie $7 D015444
- 650 _2
- $a studie proveditelnosti $7 D005240
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glykovaný hemoglobin $x metabolismus $7 D006442
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemie $x etiologie $x prevence a kontrola $7 D007003
- 650 _2
- $a hypoglykemika $x aplikace a dávkování $7 D007004
- 650 _2
- $a inzulin $x aplikace a dávkování $7 D007328
- 650 12
- $a inzulinové infuzní systémy $7 D007332
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a lyžování $x fyziologie $7 D012865
- 655 _2
- $a hodnotící studie $7 D023362
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Soupal, Jan $u 2 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 700 1_
- $a Plasova, Veronika $u 1 Department of Pediatrics, University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 700 1_
- $a Jiranova, Pavlina $u 1 Department of Pediatrics, University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 700 1_
- $a Neuman, Vít $7 xx0232676 $u 1 Department of Pediatrics, University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 700 1_
- $a Plachy, Lukas $u 1 Department of Pediatrics, University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 700 1_
- $a Pruhova, Stepanka $u 1 Department of Pediatrics, University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 700 1_
- $a Sumnik, Zdenek $u 1 Department of Pediatrics, University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 700 1_
- $a Obermannova, Barbora $u 1 Department of Pediatrics, University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague , Prague, Czech Republic .
- 773 0_
- $w MED00173679 $t Diabetes technology & therapeutics $x 1557-8593 $g Roč. 20, č. 11 (2018), s. 744-750
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30285476 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190905110203 $b ABA008
- 999 __
- $a ok $b bmc $g 1391615 $s 1050610
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 20 $c 11 $d 744-750 $e 20181004 $i 1557-8593 $m Diabetes technology & therapeutics $n Diabetes Technol Ther $x MED00173679
- LZP __
- $a Pubmed-20190405
